{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Ascentage+Pharma+Group+Inc.", "query": { "sponsor": "Ascentage Pharma Group Inc." }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Ascentage+Pharma+Group+Inc.&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T00:03:20.728Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07424833", "title": "A Study of APG-3288 in Relapsed/Refractory Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Hematological Malignancies", "Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL", "Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)", "Relapsed/Refractory Mantle Cell Lymphoma (MCL)", "Relapsed/Refractory Waldenström Macroglobulinemia (WM)", "Relapsed/Refractory Marginal Zone Lymphoma (MZL)", "Relapsed/Refractory Follicular Lymphoma (FL)" ], "interventions": [ { "name": "APG-3288", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-08", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 5, "location_summary": "Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07424833" }, { "nct_id": "NCT03080311", "title": "A Study of APG-1252 in Patients With SCLC or Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer", "Solid Tumor" ], "interventions": [ { "name": "APG-1252", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2017-02-12", "completion_date": "2020-07-17", "has_results": false, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 2, "location_summary": "Grand Rapids, Michigan • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03080311" }, { "nct_id": "NCT03781986", "title": "APG-115 in Salivary Gland Cancer Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Salivary Gland Cancer", "Salivary Gland Cancer" ], "interventions": [ { "name": "APG-115", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2019-10-28", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 3, "location_summary": "Tampa, Florida • Chicago, Illinois • Ann Arbor, Michigan", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03781986" }, { "nct_id": "NCT04260022", "title": "Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Chronic", "Myeloid Leukemia", "Chronic Myeloid Leukemia", "Philadelphia Positive Acute Lymphoblastic Leukemia", "B Cell Precursor Type Acute Leukemia" ], "interventions": [ { "name": "Ascentage Pharma HQP1351 bioavailable inhibitor", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2020-01-09", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04260022" }, { "nct_id": "NCT06051409", "title": "A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ph+ ALL", "Leukemia, Lymphoblastic, Acute, Philadelphia-Positive" ], "interventions": [ { "name": "Olverembatinib", "type": "DRUG" }, { "name": "Investigator's choice of TKI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2023-08-31", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051409" }, { "nct_id": "NCT04942067", "title": "APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Amyloidosis" ], "interventions": [ { "name": "APG-2575+ Pd", "type": "DRUG" }, { "name": "APG-2575 + DRd", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2021-12-23", "completion_date": "2024-12-01", "has_results": false, "last_update_posted_date": "2023-10-25", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 3, "location_summary": "Jacksonville, Florida • New York, New York • Cleveland, Ohio", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04942067" }, { "nct_id": "NCT06104566", "title": "Global Trial in APG2575 for Patients With CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CLL/SLL" ], "interventions": [ { "name": "lisaftoclax +BTK inhibitor", "type": "DRUG" }, { "name": "BTK inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 400, "start_date": "2023-12-20", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 11, "location_summary": "Tuscon, Arizona • Anaheim, California • Jacksonville, Florida + 8 more", "locations": [ { "city": "Tuscon", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06104566" }, { "nct_id": "NCT03386526", "title": "APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors or Hematologic Malignancies" ], "interventions": [ { "name": "APG-1387 for Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2017-11-21", "completion_date": "2022-11-30", "has_results": false, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Grand Rapids, Michigan • San Antonio, Texas", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386526" }, { "nct_id": "NCT06423911", "title": "Study of Olverembatinib (HQP1351) in Patients With CML-CP", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myeloid Leukemia", "CML", "CML, Chronic Phase" ], "interventions": [ { "name": "olverembatinib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2024-02-05", "completion_date": "2028-07-10", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06423911" }, { "nct_id": "NCT06817720", "title": "Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "olverembatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2025-10-13", "completion_date": "2027-03-07", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-07T00:03:20.728Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06817720" } ] }